- CDX bi-specific antibody for patient conditioning
- Hu-PHEC for BM/HSC transplantation
HemoGenyx LLC is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and to improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the Hu-PHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the procedure.
HemoGenyx's foundational technology is licensed from Cornell University. Their technology is based on research completed at Weill Cornell Medicine. The company also consults with Weill Cornell Medicine faculty members.